Quantitative MRI metrics associated with lesion evolution in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

Jiali Sun¹, Siyao Xu², Huabing Wang¹, Renlong Zhang³, Xiaolu Xu², Zhizheng Zhuo², De-Cai Tian¹, Xinghu Zhang¹, Yunyun Duan⁴

¹Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.

²Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.

³Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; Institute of Research and Clinical Innovations, Neusoft Medical Systems Co., Ltd., Beijing, 100094, China.

⁴Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. Electronic address: xiaoyun81.love@163.com.

PubMed DOI

Abstract

OBJECTIVES: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is characterized by demyelinating lesions that often resolve on follow-up, but imaging factors associated with lesion resolution remain unclear. Advanced quantitative MRI enables characterization of microstructural alterations and regional perfusion changes within lesions, and our study aimed to identify acute quan…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.